GO:0061737 leukotriene signaling pathway: Inflammatory Mediator Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061737 (leukotriene signaling pathway) is defined as a G protein-coupled receptor signaling pathway initiated by leukotriene binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.
• Leukotrienes are lipid mediators derived from arachidonic acid via the 5-lipoxygenase (5-LOX) enzyme, and they signal through GPCRs such as CysLT1, CysLT2, BLT1, and BLT2.
• The pathway is a druggable target in Alzheimer's disease, alpha-synucleinopathies, cancer, and metabolic disorders, with multiple antagonists and synthesis inhibitors under investigation.
• Key genes include ALOX5, ALOX5AP, LTA4H, LTC4S, CYSLTR1, CYSLTR2, LTB4R, and LTB4R2, which are frequently studied using CRISPR knockout, point mutation, and overexpression models.
• Leukotriene signaling mediates anaphylaxis to ingested antigens through intestinal mast cell-derived leukotrienes, highlighting its role in acute allergic responses.
• Research methods include GPCR signaling assays, lipidomics, calcium flux imaging, and CRISPR library screening to identify pathway modulators.
Description
The leukotriene signaling pathway (GO:0061737) is a biological process in which leukotrienes, a family of lipid mediators derived from arachidonic acid, bind to G protein-coupled receptors (GPCRs) on the surface of target cells and initiate intracellular signaling that regulates downstream cellular responses. This pathway is a key component of inflammatory and immune responses, and its dysregulation is implicated in a wide range of human diseases, including asthma, arthritis, cancer, and neurodegenerative disorders. Understanding the molecular mechanisms of leukotriene signaling is therefore of great interest for both basic research and therapeutic development. The pathway is initiated by the binding of leukotrienes, such as leukotriene B4 (LTB4) and cysteinyl leukotrienes (LTC4, LTD4, LTE4), to their respective GPCRs, leading to activation of heterotrimeric G proteins and downstream effectors. This signaling cascade ultimately modulates processes such as chemotaxis, vascular permeability, smooth muscle contraction, and cytokine production. Because of its central role in inflammation, the leukotriene signaling pathway has emerged as a druggable target in Alzheimer's disease, alpha-synucleinopathies, cancer, and metabolic disorders. Researchers studying this pathway require robust experimental models to dissect gene function and identify novel therapeutic targets. This article provides a comprehensive overview of the pathway, its key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods, including CRISPR-based genome editing.
leukotriene signaling pathway At A Glance
| GO ID | GO:0061737 |
|---|---|
| GO term | leukotriene signaling pathway |
| Ontology | biological_process |
| Synonym | none |
| Major function | G protein-coupled receptor signaling initiated by leukotriene binding, leading to regulation of downstream cellular processes |
| Key ligands | Leukotriene B4 (LTB4), cysteinyl leukotrienes (LTC4, LTD4, LTE4) |
| Key receptors | BLT1 (LTB4R), BLT2 (LTB4R2), CysLT1 (CYSLTR1), CysLT2 (CYSLTR2) |
| Synthesis enzymes | ALOX5, ALOX5AP, LTA4H, LTC4S |
| Associated diseases | Alzheimer's disease, alpha-synucleinopathies, cancer, metabolic disorders, anaphylaxis |
What Is GO:0061737?
GO:0061737, the leukotriene signaling pathway, is defined as a G protein-coupled receptor signaling pathway that begins with the binding of a leukotriene molecule to its receptor on the surface of a target cell and concludes with the regulation of a downstream cellular process. This definition encompasses the entire sequence from ligand-receptor interaction to the modulation of cellular activities, such as migration, secretion, or gene expression.
Why Is leukotriene signaling pathway Important in Cell Biology?
The leukotriene signaling pathway is critically important because it is a central mediator of inflammation and immune responses, and its dysregulation contributes to the pathogenesis of numerous human diseases, including neurodegenerative disorders, cancer, and metabolic diseases. Targeting this pathway with antagonists or synthesis inhibitors has shown therapeutic potential in preclinical and clinical studies, making it a prime focus for drug discovery. Furthermore, understanding the pathway's role in acute allergic reactions, such as anaphylaxis, is essential for developing better treatments.
• Leukotriene signaling is a key driver of inflammation and is implicated in asthma, arthritis, and allergic diseases.
• The pathway is a druggable target in Alzheimer's disease, with multiple antagonists showing promise in preclinical models.
• In alpha-synucleinopathies, leukotriene signaling contributes to neuroinflammation and neurodegeneration.
• Cysteinyl leukotriene pathway components are overexpressed in various cancers and promote tumor progression.
• The 5-lipoxygenase-leukotriene B4 axis in adipocytes controls systemic insulin sensitivity, linking the pathway to metabolic disorders.
• Intestinal mast cell-derived leukotrienes mediate anaphylaxis to ingested antigens, highlighting a role in food allergy.
• Leukotriene receptors are GPCRs, making them amenable to pharmacological modulation.
• CRISPR-based genome editing enables functional dissection of leukotriene pathway genes in disease models.
• The pathway is conserved across species, allowing translational research from mouse models to humans.
• Bioinformatics and library screening approaches can identify novel regulators of leukotriene signaling.
What Happens During leukotriene signaling pathway?
Leukotriene Synthesis and Release
In simple terms: Cells make leukotrienes from fats and release them to send signals.
Leukotrienes are synthesized from arachidonic acid through the action of 5-lipoxygenase (5-LOX, encoded by ALOX5) and 5-lipoxygenase-activating protein (FLAP, encoded by ALOX5AP). The initial product, leukotriene A4 (LTA4), is unstable and is converted either to leukotriene B4 (LTB4) by LTA4 hydrolase (LTA4H) or to leukotriene C4 (LTC4) by LTC4 synthase (LTC4S). These leukotrienes are then released from the cell and act on target cells in an autocrine or paracrine manner.
Receptor Binding and G Protein Activation
In simple terms: Leukotrienes dock onto specific receptors on the cell surface, which triggers a molecular switch inside the cell.
Leukotrienes bind to specific G protein-coupled receptors (GPCRs) on the surface of target cells: LTB4 binds to BLT1 (LTB4R) and BLT2 (LTB4R2), while cysteinyl leukotrienes (LTC4, LTD4, LTE4) bind to CysLT1 (CYSLTR1) and CysLT2 (CYSLTR2). This binding induces a conformational change in the receptor, leading to activation of heterotrimeric G proteins, typically Gi/o or Gq/11, which then modulate downstream effectors such as adenylyl cyclase or phospholipase C.
Downstream Signaling Cascades
In simple terms: The signal travels through a relay of proteins to change what the cell does.
Activation of G proteins leads to the generation of second messengers such as inositol trisphosphate (IP3) and diacylglycerol (DAG), or inhibition of cyclic AMP (cAMP) production. These second messengers trigger calcium mobilization, activation of protein kinase C (PKC), and activation of mitogen-activated protein kinases (MAPKs). Ultimately, these cascades regulate transcription factors such as NF-kB and AP-1, leading to changes in gene expression.
Cellular Responses and Regulation of Downstream Processes
In simple terms: The cell responds by moving, releasing substances, or changing its behavior.
The leukotriene signaling pathway culminates in diverse cellular responses, including chemotaxis of leukocytes, increased vascular permeability, smooth muscle contraction, and cytokine production. In the context of anaphylaxis, intestinal mast cell-derived leukotrienes mediate the response to ingested antigens, leading to systemic symptoms. The pathway is also involved in regulating insulin sensitivity through the 5-lipoxygenase-leukotriene B4 axis in adipocytes.
Key Genes Involved in GO:0061737 leukotriene signaling pathway
The following genes encode key components of the leukotriene signaling pathway, from synthesis enzymes to receptors and downstream effectors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALOX5 | 5-lipoxygenase, catalyzes the first step in leukotriene synthesis | Target for anti-inflammatory drugs; knockout models show reduced leukotriene production |
| ALOX5AP | 5-lipoxygenase-activating protein, essential for ALOX5 activity | Genetic variants linked to asthma and cardiovascular disease; target for FLAP inhibitors |
| LTA4H | Leukotriene A4 hydrolase, converts LTA4 to LTB4 | Inhibitors under investigation for inflammatory diseases; knockout reduces LTB4 levels |
| LTC4S | Leukotriene C4 synthase, converts LTA4 to LTC4 | Key enzyme for cysteinyl leukotriene synthesis; target for asthma therapy |
| CYSLTR1 | CysLT1 receptor for cysteinyl leukotrienes | Target of montelukast and other antagonists; knockout models show reduced inflammation |
| CYSLTR2 | CysLT2 receptor for cysteinyl leukotrienes | Less studied; may contribute to vascular permeability and fibrosis |
| LTB4R | BLT1 receptor for LTB4 | Mediates chemotaxis; knockout impairs neutrophil recruitment |
| LTB4R2 | BLT2 receptor for LTB4 | Low-affinity receptor; involved in cancer progression |
| PLA2G4A | Cytosolic phospholipase A2, releases arachidonic acid | Upstream regulator of leukotriene synthesis; knockout reduces substrate availability |
| GNAI1 | Gi protein alpha subunit | Mediates inhibitory signaling from leukotriene receptors |
| GNAQ | Gq protein alpha subunit | Mediates calcium mobilization from CysLT receptors |
| MAPK1 | ERK2, downstream kinase | Activated by leukotriene signaling; regulates gene expression |
| NFKB1 | NF-kB subunit, transcription factor | Drives inflammatory gene expression downstream of leukotrienes |
| PTGS2 | Cyclooxygenase-2, involved in cross-talk with prostaglandins | Modulated by leukotriene signaling in inflammation |
| TNF | Tumor necrosis factor, pro-inflammatory cytokine | Induced by leukotrienes in immune cells |
| IL6 | Interleukin-6, pro-inflammatory cytokine | Upregulated by leukotriene signaling in various cell types |
| CCL2 | MCP-1, chemokine | Induced by leukotrienes to recruit monocytes |
| ACTB | Beta-actin, housekeeping control | Used as internal control in gene expression studies |
How Is leukotriene signaling pathway Regulated?
The leukotriene signaling pathway is regulated at multiple levels. Synthesis of leukotrienes is controlled by the availability of arachidonic acid, which is released by phospholipase A2 (PLA2G4A), and by the expression and activity of ALOX5, ALOX5AP, LTA4H, and LTC4S. Receptor expression levels, desensitization, and internalization also modulate signaling strength. Additionally, cross-talk with other signaling pathways, such as the PDK1-FoxO1 axis in adipocytes, can influence leukotriene production and systemic insulin sensitivity. In disease contexts, chronic inflammation can lead to sustained upregulation of pathway components, contributing to pathology.
leukotriene signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALOX5 | Alzheimer's disease, asthma | Knockout mice, neuronal cell lines with ALOX5 KO |
| CYSLTR1 | Asthma, cancer | Receptor antagonist treatment in xenograft models, CYSLTR1 KO cells |
| LTB4R | Inflammatory arthritis, cancer | LTB4R knockout mice, chemotaxis assays |
| LTC4S | Anaphylaxis, cancer | Mast cell-specific LTC4S KO mice, tumor models |
| ALOX5AP | Cardiovascular disease, asthma | FLAP inhibitor treatment in disease models, ALOX5AP KO |
Leukotriene Signaling in Alzheimer's Disease
The leukotriene signaling pathway is a druggable target in Alzheimer's disease, where neuroinflammation contributes to disease progression. Elevated levels of leukotrienes and their receptors have been observed in Alzheimer's disease brains, and pharmacological inhibition of the pathway reduces amyloid-beta pathology and improves cognitive function in mouse models. These findings suggest that targeting leukotriene signaling could be a viable therapeutic strategy for Alzheimer's disease.
Leukotriene Signaling in Alpha-Synucleinopathies
In alpha-synucleinopathies such as Parkinson's disease and dementia with Lewy bodies, leukotriene signaling is upregulated and contributes to neuroinflammation and neurodegeneration. Inhibition of leukotriene synthesis or receptor blockade has been shown to reduce alpha-synuclein pathology and improve motor deficits in preclinical models. Thus, the pathway represents a promising target for disease-modifying therapies in alpha-synucleinopathies.
Leukotriene Signaling in Cancer
The cysteinyl leukotriene pathway is implicated in cancer, where it promotes cell proliferation, survival, migration, and angiogenesis. Overexpression of LTC4S, CYSLTR1, and CYSLTR2 has been reported in various cancers, and leukotriene receptor antagonists have shown anti-tumor effects in preclinical studies. Targeting leukotriene signaling may therefore offer a novel approach for cancer therapy.
Leukotriene Signaling in Anaphylaxis and Allergic Diseases
Intestinal mast cell-derived leukotrienes mediate the anaphylactic response to ingested antigens, highlighting a critical role for the pathway in food-induced anaphylaxis. Leukotriene receptor antagonists or synthesis inhibitors may be beneficial in managing severe allergic reactions. Additionally, leukotrienes are well-known mediators of asthma and allergic rhinitis, and drugs targeting the pathway are standard therapies for these conditions.
From leukotriene signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ALOX5 knockout reduce leukotriene production and inflammation? | ALOX5 knockout cell line (e.g., HEK293, RAW264.7) or mouse model |
| What is the effect of a point mutation in CYSLTR1 on receptor signaling? | Point mutation knock-in cell line (e.g., HEK293 expressing mutant CYSLTR1) |
| Can a tagged CYSLTR1 be used to track receptor internalization? | Knock-in of fluorescent tag (e.g., GFP) at the CYSLTR1 locus |
| Does overexpression of LTB4R enhance chemotaxis? | Overexpression cell line (e.g., HL-60 cells overexpressing LTB4R) |
| Which genes modulate leukotriene signaling in a genome-wide screen? | CRISPR library screening in a reporter cell line |
| What is the role of LTA4H in cancer cell proliferation? | LTA4H knockout cancer cell lines (e.g., A549, MCF-7) |
How to Study the leukotriene signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Study role of ALOX5, CYSLTR1 in leukotriene signaling |
| CRISPR point mutation | Specific amino acid changes | Model human SNPs in LTB4R or CYSLTR1 |
| CRISPR knock-in | Tagged protein expression | Track receptor localization and trafficking |
| Overexpression | Gain of function | Assess effect of increased LTB4R on chemotaxis |
| Lipidomics | Leukotriene levels | Quantify LTB4, LTC4 in cell supernatants |
| Calcium flux assay | Intracellular calcium mobilization | Measure GPCR activation by leukotrienes |
| RNA-seq | Transcriptome changes | Identify downstream targets of leukotriene signaling |
| CRISPR library screening | Genome-wide gene function | Discover novel regulators of leukotriene pathway |
CRISPR-Based Genome Editing
CRISPR/Cas9 technology enables precise knockout, point mutation, knock-in, and overexpression of genes involved in leukotriene signaling. Knockout cell lines for ALOX5, LTA4H, or CYSLTR1 can be generated to study their roles in leukotriene production and signaling. Point mutations can be introduced to model human genetic variants, while knock-in of tags allows visualization of receptor trafficking. Overexpression models are useful for gain-of-function studies.
Lipidomics and Metabolomics
Mass spectrometry-based lipidomics can quantify leukotriene levels in cells and tissues, providing direct readouts of pathway activity. Metabolomic profiling can identify changes in arachidonic acid metabolites upon genetic or pharmacological perturbation.
GPCR Signaling Assays
Calcium flux assays, cAMP measurements, and beta-arrestin recruitment assays are commonly used to monitor leukotriene receptor activation. These assays can be applied to cells expressing wild-type or mutant receptors to dissect signaling mechanisms.
Gene Expression Analysis
RNA-seq and quantitative PCR can measure expression of leukotriene pathway genes and downstream targets. This is useful for assessing the impact of CRISPR-mediated perturbations on the transcriptome.
How CRISPR Can Be Used to Study GO:0061737 leukotriene signaling pathway
Knockout
CRISPR knockout of genes such as ALOX5, LTA4H, CYSLTR1, or LTB4R can abolish leukotriene synthesis or signaling, providing definitive evidence of their function. These models are valuable for validating drug targets and understanding pathway contributions to disease.
Point Mutation
Introducing point mutations that mimic human genetic variants (e.g., in CYSLTR1 or LTB4R) allows researchers to study their impact on receptor function and signaling. This approach can reveal mechanisms of disease-associated mutations.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) at endogenous loci enables real-time monitoring of receptor expression, localization, and internalization. This is particularly useful for studying GPCR trafficking in leukotriene signaling.
Overexpression
Overexpression of leukotriene receptors or synthesis enzymes can enhance pathway activity and is used to study gain-of-function effects, such as increased chemotaxis or cytokine production. These models complement knockout studies.
How EDITGENE Supports leukotriene signaling pathway Research
Researchers studying leukotriene signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activity, disease progression, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for leukotriene signaling pathway research.
Frequently Asked Questions About leukotriene signaling pathway
What is the leukotriene signaling pathway?
The leukotriene signaling pathway (GO:0061737) is a G protein-coupled receptor signaling pathway initiated by leukotriene binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.
What genes are involved in leukotriene signaling?
Key genes include ALOX5, ALOX5AP, LTA4H, LTC4S, CYSLTR1, CYSLTR2, LTB4R, and LTB4R2, which encode synthesis enzymes and receptors.
What diseases are associated with leukotriene signaling?
The pathway is implicated in Alzheimer's disease, alpha-synucleinopathies, cancer, asthma, anaphylaxis, and metabolic disorders.
How can CRISPR be used to study leukotriene signaling?
CRISPR can generate knockout, point mutation, knock-in, and overexpression models to dissect gene function in the pathway.
What are the main receptors for leukotrienes?
Leukotrienes bind to GPCRs: LTB4 binds BLT1 (LTB4R) and BLT2 (LTB4R2); cysteinyl leukotrienes bind CysLT1 (CYSLTR1) and CysLT2 (CYSLTR2).
What is the role of leukotriene signaling in anaphylaxis?
Intestinal mast cell-derived leukotrienes mediate the anaphylactic response to ingested antigens.
How is leukotriene signaling regulated?
It is regulated by synthesis enzyme expression, receptor levels, desensitization, and cross-talk with other pathways such as PDK1-FoxO1.
What methods are used to study leukotriene signaling?
Common methods include lipidomics, calcium flux assays, RNA-seq, and CRISPR screening.
Can leukotriene signaling be targeted for Alzheimer's disease therapy?
Yes, preclinical studies suggest that inhibiting the pathway reduces amyloid pathology and improves cognition.
What cell models are available for leukotriene research?
EDITGENE provides custom CRISPR knockout, point mutation, knock-in, and overexpression cell models for leukotriene pathway genes.
Conclusion
The leukotriene signaling pathway (GO:0061737) is a critical mediator of inflammation and immune responses, with profound implications for human health and disease. Its roles in neurodegeneration, cancer, allergy, and metabolism make it a high-priority target for therapeutic intervention. Advances in CRISPR genome editing and bioinformatics are accelerating the functional dissection of this pathway, enabling the development of more precise and effective treatments. EDITGENE is committed to supporting this research with state-of-the-art CRISPR services and expert bioinformatics analysis.
References
- 1. Michael J et al.. 2019. The leukotriene signaling pathway: a druggable target in Alzheimer's disease.. Drug Discov Today 24(2):505-516 PMID: 30240876
- 2. Strempfl K et al.. 2022. Leukotriene Signaling as a Target in α-Synucleinopathies.. Biomolecules 12(3) PMID: 35327537
- 3. Bachtel ND et al.. 2025. Intestinal mast cell-derived leukotrienes mediate the anaphylactic response to ingested antigens.. Science 389(6760):eadp0246 PMID: 40773543
- 4. Tsai MJ et al.. 2021. Cysteinyl Leukotriene Pathway and Cancer.. Int J Mol Sci 23(1) PMID: 35008546
- 5. Sharma V et al.. 2024. Leukotriene signaling in neurodegeneration: implications for treatment strategies.. Inflammopharmacology 32(6):3571-3584 PMID: 39167313
- 6. Hosooka T et al.. 2020. The PDK1-FoxO1 signaling in adipocytes controls systemic insulin sensitivity through the 5-lipoxygenase-leukotriene B(4) axis.. Proc Natl Acad Sci U S A 117(21):11674-11684 PMID: 32393635
- 7. DuBois RN. 2003. Leukotriene A4 signaling, inflammation, and cancer.. J Natl Cancer Inst 95(14):1028-9 PMID: 12865441
- 8. Cristol JP et al.. 1989. Leukotriene receptors.. J Recept Res 9(4-5):341-67 PMID: 2556577
